Takeda Pharmaceutical Company Limited (TAK) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for joining us today, despite a very busy schedule, for FY24 Q3 earnings call by Takeda. I'm the master of the ceremony today, head of IR. My name is O'Reilly. Thank you for this opportunity. I would like to explain about the language setting first. Please find the button for the language selection at the bottom of the Zoom window. If you wish to listen in Japanese, please select Japanese. If you wish to listen to English, please select English. Or if you want to listen to the original language, please keep it off. Please select English in the Zoom language select button. Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause actual results to differ materially are discussed in our most recent Form 20F and our other SEC filings. Please also refer to the important notice on page 2 of the presentation regarding forward-looking statements and our non-IFRS financial measures, which we will also be discussing during this call. Definitions of our non-IFRS measures and reconciliations with comparable IFRS financial measures are included in the appendix of the presentation. Please refer to page 2 as well for important notices. We will begin the call. First of all, we would like to invite our CEO, Christopher Weber, to comment. Thank you, Chris. Hello, everyone, and thank you for joining us. As you might have seen from our press release, today marks an important announcement regarding our Q3 results. Milano will speak to that, and my retirement from Takeda in succession. After 12 fulfilling years with Takeda, The Board and I have agreed on June 2026 as the d...